Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16)

BMC Cancer

Table 2 Secondary cytogenetic abnormalities among patients with CBF AML

Secondary Cytogenetic Abnormalities	inv (16)		t (8; 21)		P value
Secondary Cytogenetic Abnormalities	No	%	No	%	P value
del(7q)					0.110
No	182	92.4	254	95.8
Yes	15	7.6	11	4.2
del(9q)					< 0.001
No	197	100	221	83.4
Yes	0	0	44	16.6
Trisomy 8					0.072
No	179	90.9	252	95.1
Yes	18	9.1	13	4.9
Minus X					< 0.001
No	197	100	213	80.4
Yes	0	0	52	19.6
Minus Y					< 0.001
No	196	99.5	185	69.8
Yes	1	0.5	80	30.2
Complex Cytogenetic					< 0.001
1	121	61.4	66	24.9
2	51	25.9	133	50.2
> 3	25	12.7	66	24.9
KMT2A status					0.246
Negative	196	99.5	265	100
Positive	1	0.5	0	0
FLT3-ITD Status					0.660
Negative	189	95	253	95.8
Positive	10	5	11	4.2
NPM1 Status					0.249
Negative	198	99.5	264	100
Positive	1	0.5	0	0
CEBPA Status					0.843
Negative	198	99.5	262	99.6
Positive	1	0.5	1	0.4
WT1 Status					0.296
Negative	92	95.8	112	98.2
Positive	4	4.2	2	1.8
c-Kit Mutation Exon 8					0.242
Negative	77	82.8	100	88.5
Positive	16	17.2	13	11.5
c-Kit Mutation Exon 17					0.449
Negative	83	89.2	96	85.7
Positive	10	10.8	16	14.3
c-Kit Mutation					0.649
Negative	68	73.1	85	75.9
Positive	25	26.9	27	24.1

ISSN: 1471-2407